drugset / Trial / NCT01937832
A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and Efficacy of Faropenem in community-acquired pneumonia (CAP) subjects
Timeline
- Start
- 2013-10
- Primary completion
- 2015-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ertapenem | Small molecule | 1000 mg | — |
| Subject | Faropenem | Small molecule | 1200 mg | — |
Indications
No indication recorded.